Medical education · Dr. Paola Castellano

01 Mar 2026 · In person · Dr. Paola Castellano, Vall d'Hebron · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0032—

Capture insight from this engagement

Location: Hospital La Paz
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Infusion-reaction management
Sequencing after progression
Brain-metastasis subgroup data

Scientific content used

irAE management guide

Questions raised

How should grade 2 infusion reactions be managed without steroids?
Is there subgroup data for patients with untreated brain metastases?

Notes

Medical education with radiation oncologist at Hospital La Paz. Discussed infusion-reaction management, sequencing after progression, brain-metastasis subgroup data.

Insights captured (1)

Capture insight

INS-0052Medium
Infusion-reaction management
Infusion-reaction management: practice variation observed reported by headache specialist (ES).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 3
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0032

Audit history (0)

All create, update and approval events for this record

No audit events in sample data